Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant WIDER: ribociclib plus endocrine therapy in early HR+ HER2− breast cancer
2022-503001-38-01Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: iBCFS. Planned start Jun 2025; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-503001-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503001-38-01.